JP2020530285A5 - - Google Patents

Download PDF

Info

Publication number
JP2020530285A5
JP2020530285A5 JP2020500832A JP2020500832A JP2020530285A5 JP 2020530285 A5 JP2020530285 A5 JP 2020530285A5 JP 2020500832 A JP2020500832 A JP 2020500832A JP 2020500832 A JP2020500832 A JP 2020500832A JP 2020530285 A5 JP2020530285 A5 JP 2020530285A5
Authority
JP
Japan
Prior art keywords
seq
binding molecule
sequence
domain antibody
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020500832A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020530285A (ja
JP7346378B2 (ja
Filing date
Publication date
Priority claimed from GBGB1711068.5A external-priority patent/GB201711068D0/en
Application filed filed Critical
Publication of JP2020530285A publication Critical patent/JP2020530285A/ja
Publication of JP2020530285A5 publication Critical patent/JP2020530285A5/ja
Application granted granted Critical
Publication of JP7346378B2 publication Critical patent/JP7346378B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020500832A 2017-07-10 2018-07-09 治療的psma結合分子 Active JP7346378B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1711068.5 2017-07-10
GBGB1711068.5A GB201711068D0 (en) 2017-07-10 2017-07-10 Therapeutic molecules binding PSMA
PCT/GB2018/051941 WO2019012260A1 (en) 2017-07-10 2018-07-09 THERAPEUTIC MOLECULES BINDING TO PSMA

Publications (3)

Publication Number Publication Date
JP2020530285A JP2020530285A (ja) 2020-10-22
JP2020530285A5 true JP2020530285A5 (enExample) 2021-08-19
JP7346378B2 JP7346378B2 (ja) 2023-09-19

Family

ID=59676551

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020500832A Active JP7346378B2 (ja) 2017-07-10 2018-07-09 治療的psma結合分子

Country Status (6)

Country Link
US (1) US11401342B2 (enExample)
EP (1) EP3652213A1 (enExample)
JP (1) JP7346378B2 (enExample)
CN (1) CN111051348A (enExample)
GB (1) GB201711068D0 (enExample)
WO (1) WO2019012260A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108473590B (zh) 2016-01-12 2023-04-14 克雷森多生物制剂有限公司 治疗分子
GB201607968D0 (en) 2016-05-06 2016-06-22 Crescendo Biolog Ltd Chimeric antigen receptor
WO2018127710A1 (en) 2017-01-06 2018-07-12 Crescendo Biologics Limited Single domain antibodies to programmed cell death (pd-1)
CN111683968B (zh) 2017-11-13 2024-07-05 克雷森多生物制剂有限公司 结合至cd137和psma的分子
GB201802573D0 (en) 2018-02-16 2018-04-04 Crescendo Biologics Ltd Therapeutic molecules that bind to LAG3
IL305431B2 (en) 2018-06-01 2025-03-01 Eisai R&D Man Co Ltd Antibody-drug conjugates of splicing modulators and methods of use
KR20210102274A (ko) 2018-12-13 2021-08-19 에자이 알앤드디 매니지먼트 가부시키가이샤 헤르복시디엔 항체-약물 접합체 및 사용 방법
CN113710707B (zh) * 2019-04-05 2024-05-31 特尼奥生物股份有限公司 结合于psma的重链抗体
US20220227850A1 (en) * 2019-05-15 2022-07-21 Crescendo Biologics Limited Binding molecules
GB202205589D0 (en) 2022-04-14 2022-06-01 Crescendo Biologics Ltd Mesothelin binders
WO2023199069A1 (en) 2022-04-14 2023-10-19 Crescendo Biologics Limited Chimeric antigen receptor that binds mesothelin
CN116271081A (zh) * 2023-04-04 2023-06-23 上海愿智生物技术有限公司 一种抗体偶联药物yc1605及其药物组合物和应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
ES2606537T3 (es) 2001-10-23 2017-03-24 Psma Development Company L.L.C. Anticuerpos contra PSMA
GB2398784B (en) 2003-02-26 2005-07-27 Babraham Inst Removal and modification of the immunoglobulin constant region gene cluster of a non-human mammal
GB0313132D0 (en) 2003-06-06 2003-07-09 Ich Productions Ltd Peptide ligands
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
JP2008529556A (ja) 2005-02-18 2008-08-07 メダレックス, インク. 前立腺特異的膜抗原(psma)に対するヒトモノクローナル抗体
CA2616859C (en) 2005-08-03 2015-04-14 Fraunhofer Usa, Inc. Compositions and methods for production of immunoglobulins
EP2209494B1 (en) 2007-10-09 2016-07-20 Polytherics Limited Novel conjugated proteins and peptides
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
CA2863799C (en) 2012-02-22 2020-09-01 Matthew J. FRIGAULT Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
CN103087171B (zh) 2012-12-24 2015-01-14 中国人民解放军第四军医大学 一种用于前列腺癌早期诊断和治疗的抗psma/fitc双特异性抗体及其制备方法
WO2014141192A1 (en) 2013-03-15 2014-09-18 Erasmus University Medical Center Generation of heavy chain-only antibodies
CN103333249A (zh) 2013-06-14 2013-10-02 广州康合生物科技有限公司 一种抗前列腺特异性膜抗原(psma)的单克隆抗体及其应用
WO2015142675A2 (en) 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
JP6919118B2 (ja) 2014-08-14 2021-08-18 ノバルティス アーゲー GFRα−4キメラ抗原受容体を用いる癌の治療
GB2547587B (en) 2014-10-22 2020-12-09 Crescendo Biologics Ltd Transgenic mice
EP3220956B1 (en) 2014-10-24 2023-08-09 Abzena (UK) Limited Conjugates and conjugating reagents
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
CN108473590B (zh) 2016-01-12 2023-04-14 克雷森多生物制剂有限公司 治疗分子
CN105968204B (zh) 2016-02-03 2020-01-21 中国人民解放军第三军医大学第一附属医院 一种抗前列腺特异性膜抗原的单域重链抗体
CN105968205B (zh) 2016-02-03 2019-04-26 中国人民解放军第三军医大学第三附属医院 一种抗前列腺特异性膜抗原的纳米抗体
CN105968203A (zh) 2016-02-03 2016-09-28 南昌大学 一种抗前列腺特异性膜抗原胞外区的单域重链抗体
GB201607968D0 (en) 2016-05-06 2016-06-22 Crescendo Biolog Ltd Chimeric antigen receptor
CN111683968B (zh) * 2017-11-13 2024-07-05 克雷森多生物制剂有限公司 结合至cd137和psma的分子

Similar Documents

Publication Publication Date Title
JP2020530285A5 (enExample)
JP2019511201A5 (enExample)
JP2019506155A5 (enExample)
JP7682789B2 (ja) B7-H3のIgVドメインに対するモノクローナル抗体及びその使用
JP7209464B2 (ja) ヒトインターロイキン-2に対する免疫刺激性モノクローナル抗体
JP2009539380A5 (enExample)
JP2007526233A5 (enExample)
JP2020503870A5 (enExample)
JP2009533021A5 (enExample)
RU2014120536A (ru) Белки специфического связывания и их применения
ES2637151T3 (es) Tratamiento del linfoma de células T periféricas
JP2020534830A5 (enExample)
CN111499750B (zh) 一种抗癌胚抗原的高中和活性纳米抗体及其应用
JP2014515600A5 (enExample)
CN108178799B (zh) 一种抗ca125糖类抗原的纳米抗体及其应用
CN112094348B (zh) 抗人Tim3抗体或其功能性片段及其应用
JP7357012B2 (ja) 抗bcma car抗体、コンジュゲート、および使用方法
JP2005528884A5 (enExample)
CN113227148B (zh) 抗gpc3抗体、其抗原结合片段及其医药用途
CN106164672A (zh) 用于诊断的细胞表面前列腺癌抗原
JP2015520172A5 (enExample)
CN113150152A (zh) 一种人源t细胞表面抑制性分子的特异性纳米抗体及其应用
CN105968203A (zh) 一种抗前列腺特异性膜抗原胞外区的单域重链抗体
CN105968205A (zh) 一种抗前列腺特异性膜抗原的纳米抗体
CN106928358A (zh) 一种CD105纳米抗体Nb168